Advances in hematopoetic stem cell transplantation (HSCTC) for the management of pediatric genetic disorders and malignancies have resulted in a growing population of adult survivors. With increased survival, current attention has now focused on improving treatment-related morbidities and quality of life for pediatric patients undergoing HSCTC. Infertility is one of the most common late effects and causes significant psychosocial problems for many pediatric patients, as well as for their family members.
In males, spermatogenesis can be impaired due to the toxic effects of radiation and cytotoxic chemotherapy. Determining the effects of specific types and doses of chemotherapy on spermatogenesis is difficult; however, substantial evidence now supports the view that alkylating agents and cisplatin cause the most risk for oligo-or azoospermia. 1 The gonads are highly sensitive to radiation due to their constant turnover of early germ cells. A low dose of radiation (0.1-1.2 Gy) has been shown to impair spermatogenesis, and doses of 44 Gy may result in permanent damage to sperm production. 2 Recovery of spermatogenesis depends both on total radiation dose and the dose per fraction. Leydig cells are susceptible to radiation-induced damage; however, their tolerance is higher (420 Gy). Therefore, progression through puberty with normal testosterone levels is seen in survivors, who have developed secondary sexual characteristic despite having impaired spermatogenesis. 3 Total body irradiation (TBI) is an important part of a conditioning regimen for HSCTC. Reduction of TBI dose to the testicles, in the setting of full myeloablative conditioning for hematological malignancies in order to preserve spermatogenesis may not be feasible because of increased risk of disease relapse within the testes. However, it may be a reasonable option to consider in nonmyeloablative TBI-based regimens, especially in those cases where non-malignant conditions are being treated, where there is little risk of relapse in the testes.
Our report examined the feasibility of a testicular shielding technique in two patients during administration of nonmyeloablative TBI condition for HSCTC.
Patient 1 is a 21-month-old male with mucopolysaccharidosis type 1, Hurler syndrome. He initially had received an allogeneic, partially matched, unrelated donor transplant with a preconditioning regimen consisting of rabbit anti-thymocyte globulin (RATG), fludarabine and busulfan, but experienced a primary graft failure. He was planned for a second allograft from an unrelated five out of six cord blood donor following conditioning with fludarabine, cytoxan and TBI to 2 Gy in a single fraction.
Patient 2 is a 24-month-old male with a hemizygous GATA1 mutation causing severe dyserythropoietic anemia and thrombocytopenia. He was planned to undergo an allogeneic HLA, eight out of eight matched unrelated donor bone marrow transplant with a preconditioning regimen consisting of thymoglobulin, fludarabine, cyclophosphamide and TBI to 3 Gy.
Both patients had a complete medical evaluation before the HSCT, including history and physical examination, laboratory and radiographic evaluation.
In both cases, treatment was delivered as a single fraction using anterior-posterior/posterior-anterior (AP/PA) technique, using a 6 MV photon beam. Patients were positioned in the lateral decubitus position on a stretcher against the far wall of the linear accelerator room to maximize the source to skin distance and therefore the field size, in order to encompass the entire patient. A spoiler consisting of 0.95 cm of acrylic screen was rolled in front of the patient to increase the surface dose. Testicular shield size and dose distributions with the 5 cm 2 by 8-cm thick lead block were evaluated before treatment. Measurements were taken using a Markus Chamber (Freiburg, Germany) in solid water behind the lead block. According to the National Council on Radiation Protection and Measurements (NCRP) report no. 102, 6.66 cm of lead reduces a 6 MV beam to 5%. A 5 cm 2 by 8-cm thick lead block was deemed to be most feasible.
Before TBI administration, the Radiation Oncologist placed the testicular block in front of the testes using styrofoam to adjust the height of the block to be in line with the testes. Shielding of testes was verified by projecting the block shadow through collimator light field. The block was placed for both the AP and PA fields (Figure 1 ). The dose delivered to testis was measured by optically stimulated luminescence dosimeters. They were placed on the patient's testes during entire TBI treatment.
Patient 1 treated with 2 Gy TBI received 0.712 Gy testicular irradiation, indicating 64.4% decrease in transmission. Patient 2 treated with 3 Gy TBI received 0.799 Gy testicular irradiation, indicating 73.4% decrease in transmission.
TBI to a dose of 10-12 Gy used as the conditioning regimen for HSCT can result in permanent gonadal failure. 4, 5 Furthermore, persistent decline in all domains of sexual function has also been reported in patients with prior TBI. 6 In sexually mature patients, there are numerous strategies to preserve fertility, including Figure 1 . Placement of the 5 cm 2 × 8-cm thick lead block in AP field.
cryopreservation of semen, vibratory stimulation, hormonal suppression and surgical sperm collection. 7 However, full spermatogenesis is not achieved in the majority of the pediatric population, rendering these therapies ineffective. Unfortunately, there are few preservation strategies for pre-pubertal patients who are at risk of infertility after completing radiation therapy. Newer approaches that might be applicable in this younger population, such as germ cell transplantation and testis tissue xenografting have been investigated, but remain experimental in humans.
There are several historical reports addressing testicular shielding in the setting of treatment of lymphoma or seminoma with the purpose of attenuation of externally scattered radiotherapy dose from fields placed in proximity to testicles. [8] [9] [10] [11] TBI poses a unique challenge, since testes are getting prescribed dose directly from photon beams delivered from an extended distance. Sanghvi et al. 12 carried out dosimetric study comparing dose measurement from standard two-sided (1.3-cm thick per side) lead clamshell to the single lead shields of thickness 1.3, 2.4 and 5 cm. They found that clamshell application actually resulted in dose increase, particularly with high energy photons, and the most effective dose reduction was achieved with single 5-cm lead shield.
In this report, we could demonstrate effective reduction in testicular dose exposure to o1 Gy from application of 8-cm thick lead block used from both AP and PA fields in actual patients, receiving clinically applicable 2 and 3 Gy single fraction TBI. Azoospermia has been reported to be induced by testicular radiation o 2 Gy in multiple studies ( Table 1) . Recovery of spermatogenesis depends on the dose of radiation, therefore efforts to reduce the testicular dose are warranted. As there is increasing interest in the use of non-myeloablative TBI in a setting of HSCT, this simple, yet effective method for testicular shielding needs to be revisited and highlighted to allow a better chance of fertility preservation in children. 
